Evidence map›Paper›PMID 40471218›Full record

ReviewMolecular biology reports2025

Implications of miRNA-590 dysregulation in digestive tract malignancies: mechanistic aspects and clinical significance.

Sahar Yarahmadi, Mostafa Moradi Sarabi, Zohreh Abdolvahabi, Seyedeh Sara Ghorbanhosseini, Esmaeel Babaeenezhad

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sahar YarahmadiNutritional Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
Mostafa Moradi SarabiNutritional Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
Zohreh AbdolvahabiCellular and Molecular Research Centre, Research Institute for Prevention of Non Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.
Seyedeh Sara GhorbanhosseiniDepartment of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Esmaeel BabaeenezhadNutritional Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. es.babaeenezhad1391@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digestive tract cancers are a common health concern worldwide. In recent years, dysregulation of miRNA-590 in digestive tract malignancies has been extensively studied. Alterations in its expression are related to clinical outcomes, such as tumor grade, patient prognosis, metastasis, recurrence, response to adjuvant therapy, and overall survival. Therefore, miRNA-590 has the potential to serve as a candidate prognostic and diagnostic biomarker, as well as a therapeutic target. In this study, we focus on the role of miRNA-590 in the biology of digestive tract cancers. It has been shown that miRNA-590 can act as either a tumor suppressor or an oncogene depending on the tumor type, affecting growth, invasion, angiogenesis, and resistance to chemotherapeutic agents. Additionally, we specifically discuss the downstream effects of miRNA-590 and its upstream regulators, as well as its potential as a diagnostic and prognostic marker and promising target for cancer therapy.

Indexed as

Gastrointestinal NeoplasmsGene Expression Regulation, NeoplasticMicroRNAsBiomarkers, TumorClinical RelevanceDrug Resistance, NeoplasmHumansPrognosisBiomarkers, TumorMicroRNAsMIRN590 microRNA, humanEpigeneticsGastrointestinal cancersLong non-coding RNAmiRNA-590Onco-miRNAOral cancerTumor suppressor

Identifiers

PMID40471218

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.